Stephens Investment Management Group LLC Buys 181,701 Shares of DexCom, Inc. $DXCM

Stephens Investment Management Group LLC grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 21.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,042,801 shares of the medical device company’s stock after purchasing an additional 181,701 shares during the quarter. Stephens Investment Management Group LLC’s holdings in DexCom were worth $69,211,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. CVA Family Office LLC grew its stake in shares of DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after buying an additional 147 shares during the last quarter. ORG Partners LLC grew its stake in shares of DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after buying an additional 281 shares during the last quarter. Spire Wealth Management grew its stake in shares of DexCom by 113.8% during the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock valued at $38,000 after buying an additional 305 shares during the last quarter. Aventura Private Wealth LLC bought a new position in shares of DexCom during the fourth quarter valued at about $43,000. Finally, Rothschild Investment LLC grew its stake in shares of DexCom by 59.9% during the third quarter. Rothschild Investment LLC now owns 654 shares of the medical device company’s stock valued at $44,000 after buying an additional 245 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Trending Headlines about DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom outlined a 2030 growth plan calling for at least 10% annual revenue growth through 2030, along with margin targets that suggest improving profitability over time. Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
• Positive Sentiment: The company authorized a new $1 billion share buyback, which can support the stock by signaling confidence in future cash flow and returning capital to shareholders. Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
• Positive Sentiment: Management also highlighted next-generation products, including the G8 glucose sensor and dual-analyte sensing, which could expand DexCom’s competitive position and addressable market. Dexcom to add 2 board directors with activist investor Elliott
• Positive Sentiment: DexCom and Elliott Investment Management agreed to add two independent directors to the board and revise governance, a move that may improve oversight and strategic execution. Dexcom to appoint two directors, revamp board committee with Elliott
• Neutral Sentiment: Wall Street sentiment remains constructive overall, with a “Moderate Buy” consensus and an average price target above recent trading levels, though there are still some hold and underweight ratings in the mix. Are Wall Street analysts bullish on DexCom’s stock?
• Negative Sentiment: Director Bridgette Heller sold 1,012 shares, but the transaction was small and was made under a pre-arranged trading plan, so it is less likely to be a major negative signal. Bridgette Heller Sells 1,012 Shares of DexCom (NASDAQ:DXCM) Stock

Insider Activity at DexCom

In other news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total transaction of $107,168.00. Following the completion of the transaction, the executive vice president directly owned 111,204 shares in the company, valued at approximately $7,010,300.16. This trade represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total transaction of $60,730.12. Following the transaction, the director owned 25,007 shares of the company’s stock, valued at $1,500,670.07. The trade was a 3.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,412 shares of company stock valued at $278,143 over the last quarter. Company insiders own 0.28% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of analyst reports. Weiss Ratings upgraded shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Piper Sandler reiterated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Sanford C. Bernstein set a $77.00 target price on shares of DexCom in a report on Friday, May 1st. Evercore upgraded shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 target price for the company in a report on Tuesday, March 24th. Finally, Benchmark initiated coverage on shares of DexCom in a report on Monday, May 11th. They set a “buy” rating and a $77.00 target price for the company. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average price target of $83.22.

DexCom Stock Performance

Shares of DXCM opened at $61.63 on Friday. The company has a 50-day simple moving average of $63.46 and a two-hundred day simple moving average of $65.89. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The firm has a market capitalization of $23.78 billion, a PE ratio of 26.34, a price-to-earnings-growth ratio of 1.06 and a beta of 1.40. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same period last year, the business earned $0.32 earnings per share. The business’s revenue was up 15.0% on a year-over-year basis. On average, analysts anticipate that DexCom, Inc. will post 2.56 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.